<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Genedx Holdings Corp. — News on 6ix</title>
<link>https://6ix.com/company/genedx-holdings-corp</link>
<description>Latest news and press releases for Genedx Holdings Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/genedx-holdings-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d77778dffbe2df1223b3.webp</url>
<title>Genedx Holdings Corp.</title>
<link>https://6ix.com/company/genedx-holdings-corp</link>
</image>
<item>
<title>GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-to-report-first-quarter-2026-financial-results-on-monday-may-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-to-report-first-quarter-2026-financial-results-on-monday-may-4-2026</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today</description>
</item>
<item>
<title>GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-to-launch-genetic-testing-program-with-zevra-therapeutics-to-support-patients-with-suspected-niemann-pick-disease-type-c-19</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-to-launch-genetic-testing-program-with-zevra-therapeutics-to-support-patients-with-suspected-niemann-pick-disease-type-c-19</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GAITHERSBURG, Md.--(BUSINESS</description>
</item>
<item>
<title>GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-to-present-18-abstracts-at-acmg-2026-showcasing-the-scale-of-genedx-infinitytm-and-real-world-genomic-leadership</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-to-present-18-abstracts-at-acmg-2026-showcasing-the-scale-of-genedx-infinitytm-and-real-world-genomic-leadership</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale,</description>
</item>
<item>
<title>INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/inserting-and-replacing-genedx-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-guidance-for-full-year-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/inserting-and-replacing-genedx-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-guidance-for-full-year-2026</guid>
<pubDate>Mon, 23 Feb 2026 13:07:00 GMT</pubDate>
<description>GAITHERSBURG, Md., February 23, 2026--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.</description>
</item>
<item>
<title>GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-guidance-for-full-year-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-guidance-for-full-year-2026</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024</description>
</item>
<item>
<title>TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/time-names-genedx-ceo-katherine-140500907</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/time-names-genedx-ceo-katherine-140500907</guid>
<pubDate>Wed, 11 Feb 2026 14:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., February 11, 2026--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List</description>
</item>
<item>
<title>GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-report-fourth-quarter-2025-financial-results-monday-february-23-2026-2026-02</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-report-fourth-quarter-2025-financial-results-monday-february-23-2026-2026-02</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will</description>
</item>
<item>
<title>GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-announces-preliminary-2025-financial-123000619</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-announces-preliminary-2025-financial-123000619</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., January 12, 2026--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.</description>
</item>
<item>
<title>GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-komodo-health-partner-build-133000024</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-komodo-health-partner-build-133000024</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., January 08, 2026--GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset</description>
</item>
<item>
<title>GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-announces-genomedx-prenatal-expanding-133000492</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-announces-genomedx-prenatal-expanding-133000492</guid>
<pubDate>Wed, 07 Jan 2026 13:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., January 07, 2026--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.</description>
</item>
<item>
<title>GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-appoints-dr-linda-genen-chief-medical-officer-accelerate-future-genomic-first</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-appoints-dr-linda-genen-chief-medical-officer-accelerate-future-genomic-first</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare</description>
</item>
<item>
<title>GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-leads-rare-disease-genomics-unmatched-research-and-clinical-impact-2025-2026</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-leads-rare-disease-genomics-unmatched-research-and-clinical-impact-2025-2026</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Industry-leading research powered by GeneDx Infinity™ accelerates the transition of genomics from discovery to the standard of clinical care, driving better</description>
</item>
<item>
<title>GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-present-jp-morgan-2026-healthcare-conference-2025-12-30</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-present-jp-morgan-2026-healthcare-conference-2025-12-30</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that</description>
</item>
<item>
<title>JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/jama-journal-american-medical-association-recognizes-guardian-newborn-genomic</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/jama-journal-american-medical-association-recognizes-guardian-newborn-genomic</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>Prestigious recognition underscores the impact of large-scale genomic screening in identifying serious childhood genetic conditions in conjunction with</description>
</item>
<item>
<title>GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-showcase-advancements-gene-disease-discovery-long-read-sequencing-and-more</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-showcase-advancements-gene-disease-discovery-long-read-sequencing-and-more</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Powered by GeneDx Infinity™ with unparalleled scale and diversity, GeneDx fuels breakthrough scientific research and delivers the most precise rare disease</description>
</item>
<item>
<title>GeneDx to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-participate-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-participate-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that</description>
</item>
<item>
<title>GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-reports-third-quarter-2025-financial-results-and-business-highlights-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-reports-third-quarter-2025-financial-results-and-business-highlights-2025-10</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume</description>
</item>
<item>
<title>GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-showcases-leadership-genomic-newborn-screening-icons-2025-2025-10-22</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-showcases-leadership-genomic-newborn-screening-icons-2025-2025-10-22</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>Data from more than 22,000 newborns reinforce GeneDx’s role spearheading the adoption of genomic newborn screening (gNBS) from research to clinical practice</description>
</item>
<item>
<title>GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-granted-fda-breakthrough-device-designation-its-exomedxtm-and-genomedxtm</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-granted-fda-breakthrough-device-designation-its-exomedxtm-and-genomedxtm</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel</description>
</item>
<item>
<title>GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer</title>
<link>https://6ix.com/company/genedx-holdings-corp/news/genedx-appoints-dr-mimi-lee-chief-precision-medicine-officer-2025-10-14</link>
<guid isPermaLink="true">https://6ix.com/company/genedx-holdings-corp/news/genedx-appoints-dr-mimi-lee-chief-precision-medicine-officer-2025-10-14</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>Renowned physician–scientist and healthcare innovator to lead GeneDx’s vision for a new era of lifelong health informed by genomics GAITHERSBURG,</description>
</item>
</channel>
</rss>